Tempo

What Is Tempo

Tempo is an at-home monitoring service for people living with congestive heart failure (CHF). The platform bundles a connected scale, a blood-pressure cuff, and a daily symptom check into an AI-powered early-warning model that detects fluid retention days before a clinical crisis materializes. When the model flags a deterioration signal, it routes an alert directly to the patient's care team — enabling intervention before an ER visit becomes unavoidable.

Who It Serves

Tempo operates on a B2B2C model with two distinct customer layers.

Why Now — Three Converging Forces

1. A Growing CHF Epidemic

2. Value-Based Payment Pressure With Real Teeth

The Hospital Readmissions Reduction Program (HRRP) penalizes general acute-care hospitals when excess Medicare readmissions occur within 30 days. Heart failure is one of six named conditions. Key figures for the current fiscal year:

3. A Rapidly Expanding RPM Infrastructure

The Headline Opportunity

Strategic Logic

Tempo's commercial case is structurally sound across three dimensions:

• Payer alignment: Hospitals bear a named, measured financial penalty for CHF readmissions under HRRP.
• Reimbursement infrastructure: CMS CPT codes for RPM already exist, enabling billing without new policy creation.
• Market validation: Cardiology is the single largest RPM indication by revenue share at 29.0%.

The combination of a growing patient population (6.7M → 11.4M by 2050), tightening CMS penalties ($521M kept by Medicare this FY), and a maturing AI-enabled monitoring market positions Tempo to enter a space where the payer, the care provider, and the regulatory framework are already aligned around the problem it solves.

A structured breakdown of the problem, the financial stakes, the regulatory lever, and the market window.

1. The Epidemic That Won't Plateau

Heart failure is not a stable chronic condition — it is an accelerating public health crisis. Approximately 6.7 million Americans over the age of 20 currently live with heart failure. That figure is projected to grow ~70% over the next quarter-century, driven by an aging population, rising rates of hypertension and obesity, and improving short-term survival that converts acute events into long-term disease burden. HF rates have steadily increased over the last decade and are growing more severe particularly in younger populations, racial and ethnic minority groups, and those with multiple health conditions.

2. The Specific, Costly Failure Point: The 30-Day Readmission

Within the broader HF burden, one clinical event crystallizes the problem for payers and providers: the preventable readmission. CHF is one of the leading causes of inpatient hospitalization readmission in the United States, with readmission rates remaining above the 20% goal within 30 days. The window compounds rapidly — and each return carries a steep price tag.

The clinical mechanism is well-understood: fluid accumulates gradually in the days before a crisis, producing detectable physiological signals — weight gain, rising blood pressure, worsening breathlessness — that go unmonitored once the patient goes home. By the time a symptom becomes unmistakable, decompensation has often progressed to the point where hospitalization is unavoidable. Tempo is designed to close exactly that surveillance gap.

3. The Payer Penalty That Makes This a Hospital Problem

The readmission crisis is not just a clinical failure — it is a direct financial threat to hospital balance sheets, created and enforced by CMS policy. The Hospital Readmissions Reduction Program (HRRP), created as part of the Affordable Care Act, punishes general acute-care hospitals when more Medicare patients return within 30 days of discharge than the government deems appropriate. Critically, the penalty applies to all Medicare fee-for-service payments — not only readmission-related payments.

This regulatory mechanism is Tempo's primary commercial lever. It converts what might otherwise be a quality-improvement conversation into an urgent, quantified financial problem that CFOs and CMOs must address. The penalty you are paying today funds the ROI of deploying us tomorrow.

4. The Market Window: RPM at an Inflection Point

The infrastructure conditions for Tempo's model are now in place. Remote patient monitoring has shifted from a niche clinical tool to a mainstream delivery mechanism. Cardiology is the largest single specialty within the U.S. RPM market at 29% of the base. CHF was already the largest single-condition segment in global cardiac RPM as of 2021, at $916.75 million in revenue. CMS has provided the reimbursement scaffolding via CPT codes 99453, 99454, and 99457, and hospital-at-home programs are approved in 37 states.

5. The Three Converging Forces

The Epidemic Driving the Opportunity

Approximately 6.7 million Americans over the age of 20 currently live with heart failure. The lifetime risk of developing HF has risen to 24% — roughly 1 in 4 people. The financial stakes are equally severe: annual direct medical costs currently stand at $24.7 billion (projected to rise to $77.7 billion), with total HF-related expenses potentially reaching $858 billion by 2050.

The Regulatory Hammer: HRRP Penalties

Tempo's B2B buyers face hard financial penalties under the Hospital Readmissions Reduction Program (HRRP), established by the Affordable Care Act. Heart failure consistently produces the highest readmission rates of the six tracked conditions — often running 18–22% nationally. Tempo's early-warning model directly attacks this liability.

TAM — Total Addressable Market

Tempo operates within the U.S. Remote Patient Monitoring (RPM) market, which provides the broadest relevant ceiling for the opportunity. Key drivers include the growing elderly population — the U.S. population aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050 — and demand for cost-effective healthcare.

SAM — Serviceable Addressable Market

Tempo is purpose-built for cardiac and CHF patients, not the full RPM universe. The cardiology segment accounted for the largest share — 29.0% — of the U.S. RPM market in 2024, confirming it as the single largest clinical application within the RPM landscape. Applying this 29% share to the $16.09B 2025 U.S. RPM base yields the estimated SAM below.

SOM — Serviceable Obtainable Market

Tempo's go-to-market is B2B2C — routing through health systems and ACOs to reach enrolled CHF patients. ARPU of $150–$200/month is modeled on CMS CPT code reimbursement benchmarks (CPT 99453/99454/99457). The table below shows the bottom-up enrollment and revenue ramp.

Market Dynamics Favoring Tempo

Tagline: *Catch heart failure before the ER does*

Tempo operates a B2B2C model: hospitals and ACOs are the institutional buyers; Medicare-enrolled CHF patients are the end beneficiaries. The two segments are tightly interdependent — institutional pain drives the purchase decision; patient engagement determines clinical outcomes.

Segment 1 — Primary B2B Buyers: Hospitals & ACOs Penalized Under HRRP

Who They Are

The Hospital Readmissions Reduction Program (HRRP), created under the Affordable Care Act, penalizes general acute-care hospitals when excess Medicare readmissions occur within 30 days of discharge. The HRRP covers six index conditions, including heart failure, and critically applies payment reductions to all Medicare fee-for-service payments — not only readmission-related payments — dramatically amplifying financial exposure. ACOs are a parallel and equally motivated buyer segment, with RPM for CHF patients specifically studied as a mechanism for reducing post-hospitalization mortality, readmissions, and ED visits.

Jobs-to-Be-Done

Financial Pain Point

Heart failure consistently produces the highest readmission rates of the six HRRP conditions — 18–22% nationally — and accounts for up to 26.9% of total readmission rates at a treatment cost of $15,000–$25,000 per patient. Post-discharge RPM is now reimbursable under Medicare, reducing the net cost of intervention.

An ACO-based study of comprehensive RPM for HF patients found a 52% reduction in total cost of care among enrolled heart failure patients, with the majority of savings attributed to reductions in hospital and post-hospital discharge spending.

How to Reach Them

• Direct enterprise sales targeting CMOs, Quality Officers, and VP-level Population Health executives at the ~2,583 HRRP-penalized hospitals — a named, publicly available list from CMS
• ACO network partnerships leveraging shared-savings alignment; RPM enrollment in post-discharge CHF cohorts directly supports ACO quality benchmarks
• Clinical evidence and peer referral via cardiology department heads; evidence supports significant reductions in hospitalizations, length of stay, and ED visits alongside improved patient quality of life
• CMS quality reporting channels and healthcare conference presence (ACC, AHA, HIMSS) where penalized hospital leadership actively seek readmission reduction solutions

Segment 2 — End Patients: Medicare-Enrolled CHF Patients

Who They Are

6.7 million Americans are currently living with heart failure (age 20+). The population is projected to grow significantly over the coming decades. Approximately 55–60% are Medicare beneficiaries, representing a core addressable end-patient pool of roughly 3–4 million Medicare-enrolled CHF patients.

These patients are typically older adults managing multiple comorbidities — including diabetes, hypertension, coronary artery disease, vascular disease, and history of stroke — often with limited health literacy, fixed incomes, and dependence on caregivers for daily management. CHF is the most common cause of hospital readmissions among elderly and Medicare patients.

Jobs-to-Be-Done

Clinical Stakes

How to Reach Them

• Hospital discharge workflow: Tempo is enrolled at the point of hospital discharge — the highest-intent moment for patient adoption — where the care team prescribes the service
• Cardiology and primary care referral networks: Heart failure clinics and cardiologist practices identify high-risk patients during routine follow-up
• Care navigators and transitional care teams: Post-discharge nurse navigators are the most efficient enrollment channel, already in contact with the target patient
• Caregiver and family engagement: Adult children and caregivers of elderly CHF patients are a secondary influencer segment critical to device adoption and daily adherence

Segment Summary

Market Structure

The competitive field is organized into three strategic tiers:

• Tier 1 — Enterprise Health-IT / Medtech Giants
• Tier 2 — Cardiac RPM Specialists
• Tier 3 — General RPM Platforms & Data Infrastructure

Tier 1 — Enterprise Medtech Incumbents

Philips Healthcare / BioTelemetry

Philips is described in 2026 market analyses as the leader in "Hospital-to-Home" transitions with the most mature enterprise-grade software platform. In September 2025, Royal Philips entered a national partnership with Optum Healthcare, including its Mobile Cardiac Telemetry (MCOT) and Extended Holter solutions. Philips has transitioned from a hardware-first company to a software-centric intelligence provider — but sells to health system CIOs, not directly to the HF care team, leaving a workflow integration gap.

Gap vs. Tempo: Competes on breadth (COPD, stroke, arrhythmia) rather than CHF-specific fluid-buildup detection. Solutions are primarily arrhythmia-oriented, not optimized for weight-gain / hemodynamic pattern recognition that predicts decompensated HF.

Medtronic

Medtronic's CareLink Network connects implantable devices (CRT-D, ICD, pacemaker) to healthcare teams. Medtronic is the recommended RPM partner primarily when the need is cardiac-device monitoring.

Gap vs. Tempo: Implant-centric by design. The majority of the ~3–4 million Medicare CHF patients Tempo targets have no implanted device and are unserved by Medtronic's ecosystem.

GE HealthCare

GE HealthCare has explicitly moved toward at-home care, tapping virtual care company Biofourmis to extend patient monitoring from hospitals into patients' homes — underscoring that GE is building this capability via M&A rather than an organic CHF-specific product.

Tier 2 — Cardiac RPM Specialists

Biofourmis / CoPilotIQ (merged Oct 2024)

The closest direct analogue to Tempo. CoPilotIQ acquired Biofourmis to deliver in-home care across the full spectrum from pre-surgical optimization to acute, post-acute, and chronic care.

Platform highlights:

• Biovitals® analytics engine captures over 4 million data points per post-acute care patient per day
• 21 proprietary AI algorithms for care delivery, several FDA-cleared
• Demonstrated 38% readmission reduction
• 2025 valuation estimated above $1.3B
• Revenue mix has shifted from hardware to high-margin subscriptions and per-patient fees

Gap vs. Tempo: Requires proprietary biosensor hardware — high-complexity, high-cost implementation difficult for mid-sized hospitals and ACOs. Hospitals and payers are struggling with overwhelming complexity and cost to manage multiple point solutions. Tempo's purpose-built CHF kit (scale + cuff + symptom check) is a simpler, faster-to-deploy alternative.

iRhythm Technologies

iRhythm's Zio patch enables real-time data transmission and AI-driven arrhythmia detection. Primarily an arrhythmia (AFib) detection company — does not compete directly on HF fluid-buildup monitoring.

AliveCor

AliveCor's Kardia 12L is FDA-cleared to detect 35 conditions, including acute myocardial infarction. Focus is ECG/rhythm-based cardiac events — not the weight and fluid dynamics that drive CHF decompensation.

Tier 3 — General RPM Platforms & Data Infrastructure

Validic

In February 2025, Validic introduced a generative AI-powered RPM assistant through its Validic Impact solution. Positioned as infrastructure middleware — the recommended choice when the main challenge is integrating patient-generated health data into the EHR, not a clinical decision-support product with its own alert logic.

OMRON Healthcare

OMRON's 2025 rollout of "VitalSight" uses a "kit-in-a-box" model that lowers the barrier to entry for RPM in small-to-mid-sized clinics. OMRON supplies the hardware layer but provides no disease-specific predictive model for CHF decompensation — making it a potential supplier/partner, not a direct competitor.

Full Competitive Positioning Matrix

Three Structural Gaps Tempo Can Exploit

1. Condition Specificity

The incumbent field is split between implant-centric platforms (Medtronic) and broad multi-condition RPM suites (Philips, Validic). Conventional wired systems retained 59.78% of 2024 cardiac monitoring revenue, yet AI-enabled platforms register the highest growth trajectory — signaling the market is moving toward predictive intelligence precisely where no single CHF-focused product yet dominates.

2. Mid-Market Hospital Access

Incumbent solutions are premium-priced, and for smaller practices, the total cost of ownership remains a significant barrier compared to leaner competitors. The 2,583 HRRP-penalized hospitals span a wide range of system sizes; many mid-tier hospitals lack the procurement budget and IT staff to deploy enterprise Biofourmis or Philips programs.

3. HRRP Financial Urgency

Competitors position on clinical outcomes; none lead with Medicare penalty avoidance as a primary ROI frame. The HRRP 3% penalty on all Medicare DRG payments creates a quantifiable, CFO-visible financial risk that a CHF-specific readmission product can directly address — a sales narrative that broad RPM suites cannot cleanly own.

Target Patient Population

1. The Core Wedge: Condition-Specific Intelligence

Most RPM platforms — including Vivify Health, Health Recovery Solutions, Teladoc–Livongo, Amwell, and iHealth Labs — are horizontal infrastructure: generic data pipes across many chronic conditions. Tempo is purpose-engineered around the specific hemodynamic signature of decompensating CHF: fluid accumulation, rising blood pressure, and declining symptom tolerance appearing in combination, days before a crisis.

The sensor bundle (scale + blood-pressure cuff + daily symptom check), the early-warning model, and the alert routing logic are all built around this single disease mechanism. Tempo cannot easily be repurposed as anything else — and that constraint is intentional. It allows the model to train on a narrow, high-signal dataset and allows Tempo to speak the clinical language of heart failure care teams rather than the administrative language of platform IT buyers.

2. The Buyer Trigger: Structural, Non-Discretionary Loss Aversion

Tempo's differentiation is financial and regulatory, not just clinical. The Hospital Readmissions Reduction Program (HRRP) penalizes hospitals when excess Medicare readmissions occur within 30 days of discharge — reducing *all* Medicare admission payments based on the excess readmission ratio, not just payments for readmissions.

Tempo is positioned as a direct cost-offset against HRRP penalty exposure — an argument that routes to a CFO, not just a CMO. This buying motivation is anchored in loss aversion rather than aspiration, making it structurally more durable than discretionary technology spend.

3. The AI Layer: A Compounding Data Flywheel

Tempo's early-warning model improves with every enrolled patient. Each CHF patient contributes longitudinal weight, blood pressure, and symptom trajectories labeled against actual decompensation events — capturing variation by ejection fraction, comorbidity burden, medication regimen, and demographic subgroup. A competitor entering later cannot buy this dataset; they have to generate it.

This creates a data flywheel: prediction accuracy widens as the enrolled population grows, making the early-warning signal progressively harder to replicate. The AI-enabled RPM platform sub-segment is growing at a 6.89% CAGR — the highest growth rate within cardiac home monitoring — reflecting where clinical and commercial value is concentrating.

4. Competitive Landscape

The nearest competitive analog is Biofourmis (now CoPilotIQ), which delivers AI-driven RPM combining wearable/medical-device data with analytics to predict health deterioration early. However, Biofourmis has broadened significantly — serving cardiology, oncology, post-acute care, complex chronic disease management, hospital-at-home programs, and pharmaceutical clinical trials.

This breadth is Biofourmis's commercial strength and Tempo's opening: a platform serving pharma trials, oncology, and hospital-at-home simultaneously cannot be optimally tuned for CHF readmission prevention specifically.

HRS and Cadence address post-acute and transitional care but neither offers a CHF-specific predictive fluid-retention model. Tempo differentiates from both by leading with clinical evidence tied to a single disease mechanism rather than a workflow integration story.

5. The B2B2C Model: Institutional Switching Costs

Tempo sells to hospitals and ACOs — not patients directly. Once deployed, it is integrated into three layers that collectively raise the cost of switching:

• Clinical workflows — care team alert routing, EHR handoffs
• Quality reporting infrastructure — excess readmission ratio tracking
• Patient onboarding pathways — discharge protocols that hand patients a Tempo kit

Replacing a working RPM deployment requires retraining staff, re-contracting devices, re-validating alert thresholds with the clinical team, and absorbing months of monitoring gap risk. The longer Tempo is embedded, the harder it becomes to displace — independent of a competitor's feature set.

6. Regulatory Position: A Two-Sided Barrier

FDA 510(k) clearance as a Software as a Medical Device (SaMD) may be required for Tempo's AI deterioration prediction algorithm. This is both a cost and a moat. Once achieved, clearance:

1. Signals clinical credibility to hospital CMOs and quality officers who require evidence-based tools
2. Raises the bar for new entrants, who must navigate the same regulatory process before competing on the same clinical claims
3. Unlocks CMS reimbursement pathways — specifically CPT codes 99453, 99454, and 99457 — sustaining the per-patient recurring revenue model

7. Moat Summary

What Tempo Is

Tempo is a B2B2C remote patient monitoring (RPM) service sold to hospitals and ACOs and delivered to Medicare-enrolled CHF patients at home. It bundles a connected weight scale, a blood-pressure cuff, and a daily symptom check-in into an AI-powered care layer that synthesizes data streams into a fluid-retention early-warning score. When the model flags deterioration, it routes a structured alert to the patient's care team — enabling medication adjustment or a telehealth touch before the patient reaches the ED.

Clinical logic: Sudden weight gain is one of the earliest signs of fluid retention in CHF, often appearing days before symptoms worsen. Tempo's differentiator is fusing weight trend, BP trend, and symptom trajectory into a composite score — moving beyond the industry-standard "2–3 lb in a day / 5 lb in a week" single-threshold rule used by most point solutions.

The Two Core Roles

Patient Side: A CHF patient discharged from a Tempo-contracted hospital receives a pre-paired kit — scale, cuff, hub — requiring no Wi-Fi, app download, or Bluetooth pairing. Each morning the patient steps on the scale and takes BP; readings transmit automatically via cellular. A 60-second voice/SMS symptom check closes the daily loop.

Clinician Side: The care team (cardiologist's MA, nurse care manager, or ACO-embedded RN) sees a prioritized worklist ranked by composite deterioration score — not raw device data. A yellow flag means "watch"; red means "call within 2 hours."

MVP Feature Set

The MVP tests one riskiest assumption: will a contracted health system's care team reliably act on Tempo alerts, and will that action demonstrably reduce 30-day readmissions within a single performance period? Everything else is deferred.

Reimbursement Architecture

Tempo's ARPU is grounded in existing CMS fee schedules. The billing stack per enrolled patient per month:

Key User Flows

Flow 1 — Patient Enrollment (Day 0–3 Post-Discharge)

1. Hospital discharges CHF patient
2. ADT feed triggers Tempo enrollment queue
3. Tempo ops ships pre-paired kit (arrives Day 1–2)
4. Phone-based onboarding call (<15 min): baseline weight captured, symptom profile recorded, daily routine set
5. Patient active — daily transmissions begin

Flow 2 — Daily Morning Loop (Recurring)

1. Patient steps on scale + takes BP (auto-transmits via cellular)
2. SMS/IVR symptom check fires (60 sec, 3 questions)
3. Tempo model scores the day's composite signal
4. Dashboard updates patient's flag status (green / yellow / red)
5. If yellow/red → care team notified via dashboard alert + SMS page

Flow 3 — Alert Resolution (Clinician)

1. RN receives red alert for Patient X
2. Dashboard shows: +4.2 lb over 48 hrs, BP elevated, reports ankle swelling
3. RN places outbound call (documents time for CPT 99457 billing)
4. Clinician adjusts diuretic, schedules telehealth follow-up, or escalates
5. One-click "resolved" close-out — timestamp logged for audit trail
6. Readmission avoided → HRRP penalty exposure reduced for hospital

Product Principles

Regulatory Milestone: The SaMD Question

This is Tempo's highest-stakes pre-launch dependency. Tempo's deterioration-prediction algorithm almost certainly qualifies as Software as a Medical Device (SaMD).

Riskiest Assumption — What the MVP Must Test First

The MVP's singular job is to validate a three-link chain. All three links must hold for the business model to function.

Tempo operates across three overlapping regulatory regimes — FDA device/software regulation, CMS reimbursement policy, and HIPAA/data security law — each with distinct approval gates, timelines, and cost implications that must be planned for in parallel.

1. FDA Regulatory Pathway — Software as a Medical Device (SaMD)

Governing regime: 21 CFR Part 880 / FDA SaMD Framework

Tempo's AI deterioration-prediction algorithm — its most commercially differentiable feature — is also its most significant regulatory exposure. The FDA regulates AI-driven monitoring systems under the SaMD category. Because Tempo's algorithm informs clinical care decisions for a vulnerable cardiac population, it is most likely classified as a moderate-risk (Class II) device, making the 510(k) clearance pathway the presumptive route.

As of August 2024, the FDA cleared 97% of AI-enabled devices via the 510(k) pathway. Unlike PMA, 510(k) does not require new clinical trials, enabling faster market entry for digital tools. Most AI/ML devices have been Class II devices cleared via 510(k) by demonstrating "substantial equivalence" to a predicate device.

Hardware Devices

Tempo's connected scale and blood-pressure cuff both require 510(k) clearance to meet CMS billing requirements. Established predicate devices exist for both, which meaningfully shortens the hardware clearance path if Tempo sources FDA-cleared OEM hardware components rather than developing novel device hardware from scratch.

Post-Market Algorithm Updates — The PCCP Mechanism

A Final Guidance on Predetermined Change Control Plans (PCCPs) for AI-enabled device software functions was published in December 2024, allowing manufacturers to pre-specify how algorithms will be updated post-market without requiring a full resubmission for each change. It applies to 510(k), De Novo, and PMA submissions.

Tempo should embed a PCCP into its initial 510(k) submission. Without this, every material model update restarts the FDA review clock — a structural competitive disadvantage in an AI product category where model improvement is continuous.

Additionally, on January 6, 2025, the FDA published Draft Guidance: *"Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations."* Tempo's regulatory team should treat this as a near-final reference for submission planning.

Estimated FDA Timeline & Cost

2. CMS Reimbursement Compliance — The Revenue Engine

Governing regime: CMS Medicare Physician Fee Schedule (MPFS); CPT Codes 99453 / 99454 / 99457 / 99458

Reimbursement is not just a financial consideration — billing errors under CMS rules constitute fraud and abuse exposure under the False Claims Act. Tempo's ARPU of ~$150–$200/month is anchored to the RPM code structure below.

3. HIPAA & Data Security Compliance

Governing regime: HIPAA Privacy Rule, Security Rule, Breach Notification Rule; HHS NPRM (January 2025)

For Tempo, PHI flows through at minimum five distinct layers: the connected device, the patient's home network, Tempo's cloud platform, the care team alert interface, and the hospital/ACO EHR system. A failure at any single layer exposes the entire program.

Key HIPAA Compliance Requirements for Tempo

• Encryption & Technical Safeguards: Proposed HHS changes would eliminate the "addressable" designation for most safeguards, making encryption, multi-factor authentication (MFA), network segmentation, and annual penetration testing mandatory.
• FDA Cybersecurity (Connected Devices): The FDA's premarket cybersecurity guidance (updated 2023, enforced 2025–2026) requires Tempo's 510(k) submission to include a cybersecurity documentation package — including a Software Bill of Materials (SBOM) and vulnerability disclosure policy — as a condition of clearance.
• Business Associate Agreements (BAAs): Every hospital or ACO that deploys Tempo will require a BAA. Tempo's standard commercial contract must include this as a non-negotiable baseline term.
• State Privacy Laws: California (CMIA), New York (SHIELD Act), and Texas (THIPA) are the three highest-priority states given their large Medicare CHF populations and active enforcement environments. Multi-state deployment requires a state privacy law mapping exercise before launch.

4. Regulatory Risk Summary & Timeline

5. Strategic Compliance Posture

Three regulatory design choices will have outsized impact on Tempo's go-to-market speed and cost:

1. How Tempo Makes Money

Tempo operates a B2B2C subscription model: health systems, hospital networks, and ACOs contract with Tempo and deploy the service to their enrolled CHF patients. Revenue flows from the institutional buyer — not the patient — making Tempo's commercial motion a provider-facing enterprise SaaS sale with a per-patient recurring revenue structure.

The model is engineered around a specific financial pain point: the Hospital Readmissions Reduction Program (HRRP), a CMS pay-for-performance program first implemented in FY 2013. It reduces Medicare IPPS payments to hospitals whose risk-adjusted 30-day unplanned readmission rates exceed CMS benchmarks for six conditions — including heart failure. Payment reductions are capped at 3% (a payment adjustment factor of 0.97) and applied to all Medicare fee-for-service base operating DRG payments.

This positions Tempo as a cost-avoidance tool rather than a discretionary technology purchase — its value proposition maps directly to a named line item on a hospital CFO's operating budget.

2. Revenue Streams

3. The Reimbursement Anchor: CPT Code Stack

Tempo's PPPM pricing is anchored to CMS RPM billing codes that hospital partners use to recapture reimbursement from Medicare — making the service self-funding or near-self-funding for the provider under a well-run program.

Two new RPM codes were introduced in 2026 — 99445 (2–15 days of measurement) and 99470 (first 10 minutes of monitoring time) — offering providers greater flexibility. Reimbursements for RPM are higher in 2026 than in 2025.

4. Pricing Approach & Tiers

Tempo prices as a per-patient-per-month SaaS subscription sold to the institutional buyer, set below the provider's achievable CMS reimbursement — creating a clear margin for the health system and a natural incentive to enroll more patients.

5. Unit Economics (Per-Patient Monthly P&L, Steady-State)

6. Revenue at Scale (SOM Bridge)

7. Why the Payment Model Is Defensible

Three structural forces lock in Tempo's commercial model:

1. The Commercial Beachhead: Who Feels the Pain First

Tempo's primary buyer is not the patient — it is the hospital or ACO administrator who receives a CMS penalty notice every fiscal year.

The Hospital Readmissions Reduction Program (HRRP) penalizes hospitals with higher-than-expected 30-day readmission rates across six targeted conditions, including heart failure. Penalties apply across all Medicare admissions — not just those that resulted in readmissions — and are capped at 3% of a hospital's total Medicare reimbursement.

A structural quirk makes demand for readmission-reduction tools permanently durable: HRRP penalties are calculated on a curve against average hospital performance, meaning a fixed share of hospitals will always be penalized regardless of national improvement trends.

2. The Reimbursement Engine: Why B2B2C Works

Tempo does not depend on discretionary hospital budget. It rides existing Medicare RPM billing infrastructure via stackable CPT codes.

3. The Wedge Motion: Start Where the Pain Is Sharpest

Tempo's initial GTM motion is deliberately narrow: post-discharge CHF patients at HRRP-penalized health systems in the top 20 U.S. metropolitan markets.

Three reasons this wedge works:

① The penalty is immediate and measurable. A hospital facing a 1.5% HRRP payment reduction has a CFO-legible dollar figure Tempo can compete against directly. Sales cycles begin with Quality/Care Transitions teams and land at the CMO/CFO level.

② The patient is already identified. Medicare CHF patients within 30 days of discharge are already flagged as high-risk in hospital EHR systems. The hospital knows who they are — Tempo gives them a tool to act.

③ Reimbursement is pre-validated. Tempo embeds RPM billing code workflows directly into its care-team dashboard, reducing billing friction for the health system.

4. The Market: Headroom Is Large and Growing

Competitive Landscape

Leading RPM players include Philips Healthcare, Medtronic, GE Healthcare, Abbott Laboratories, Boston Scientific, Dexcom, ResMed, Masimo, Omron Healthcare, AliveCor, Teladoc Health, Vivify Health, BioTelemetry, and iRhythm Technologies. These are largely horizontal platforms or device-focused players. In 2024, GE Healthcare partnered with Biofourmis to blend AI-powered chronic disease solutions — illustrating that AI-layer partnerships are emerging. Startups such as CareSimple and TimeDoc hold niche footholds, but no player yet owns the "HRRP penalty reduction for CHF" positioning that Tempo is targeting.

5. How Growth Compounds: The Flywheel

Tempo's growth model is not linear. Each signed health system creates compounding leverage:

• Outcome evidence from enrolled patients strengthens the sales pitch to the next health system
• ACO and payer conversations open via shared savings contracts
• CMS hospital-at-home program eligibility is unlocked
• Patient panel expands within each system: CHF → COPD → HF with preserved ejection fraction

Large health systems and integrated delivery networks are expected to hold the leading end-user share of the RPM market in 2025, given their clinical staff, IT infrastructure, and reimbursement relationships — making deep health system relationships a durable distribution moat. The patients segment is expected to expand at the fastest rate throughout the RPM forecast period, driven by rising chronic disease prevalence and growing preference for home health services — reducing patient-level adoption friction over time.

6. Key Go-to-Market Risks & Mitigations

7. GTM Summary Snapshot

1. Market Backdrop

Tempo enters a U.S. RPM market undergoing sustained structural expansion. Growth is fueled by the digitization of healthcare delivery, adoption of telemedicine, rising prevalence of chronic illness, favorable insurance coverage policies, and innovations in AI-based monitoring solutions. Tempo's cardiac focus sits in the single largest application segment — cardiology accounted for 29.0% of the U.S. RPM market in 2024.

2. Addressable Market Sizing

3. Revenue Model & ARPU

Tempo's primary revenue mechanism runs through Medicare RPM billing codes, with the health system or ACO as the billing entity and Tempo as a contracted platform provider.

The CMS 2026 Physician Fee Schedule lowered the data transmission threshold so that the setup code now requires only 2 days of monitoring data to qualify for reimbursement, reducing billing failures in the first month of enrollment.

4. SOM Build — Bottom-Up Revenue Projection

At scale, this represents a ~4–9% capture of the estimated $4.1–4.7B cardiac RPM SAM — a defensible range for a B2B platform with concentrated health system distribution and no need to acquire patients individually.

5. Demand-Side Drivers

6. Competitive Context

Tempo will not operate in a vacuum. Key competitor categories include:

• Post-acute / transitional care (30–90 day episodes): HRS and Cadence are optimized for HRRP readmission penalty reduction workflows.
• Hospital-at-home (24/7 command centers): Biofourmis, Current Health, and Inbound Health are already positioned.
• Consolidated threat: In October 2024, Biofourmis merged with CopilotIQ, combining wearables, FDA-cleared AI, clinician dashboards, and patient mobile apps into a more scaled competitor.

Tempo's differentiation case must rest on CHF-specific clinical depth, AI model accuracy in fluid-retention prediction, and the focused simplicity of its hardware bundle — advantages that broad-condition platforms structurally cannot match.

7. Key Financial Risks

8. Summary Outlook

At the midpoint of its SOM range — roughly $270M in annual revenue at Year 3 — Tempo would represent approximately 6% of the cardiac RPM addressable market, served through roughly 125,000 active CHF patients. That is a commercially achievable goal *if* health system sales cycles are managed tightly, CMS reimbursement rates hold, and the AI model achieves regulatory clearance without material delay. Each of those conditions carries uncertainty, and the projections above should be stress-tested against slower ramp, lower ARPU, and a deferred launch scenario before any capital commitment is finalized.

5.1 Founding Team Gaps — Honest Assessment

Tempo sits at the intersection of three demanding disciplines — clinical cardiology, regulated software (SaMD), and B2B health-system sales. Most early founding teams are strong in one or two of these vectors and thin in the third.

5.2 Why Regulatory Leadership Is the Highest-Priority Hire

Tempo's AI deterioration-prediction algorithm almost certainly meets the FDA's definition of Software as a Medical Device. The cost of discovering you are on the wrong side of the SaMD classification line after shipping is measured in years and hundreds of thousands of dollars.

Misclassification is one of the biggest reasons digital health startups face delays, rejection, or unexpected regulatory burdens. Hiring experienced regulatory affairs leaders has become one of the most difficult executive recruitment challenges in MedTech — director-level positions often remain open for months, and VP of Regulatory Affairs searches frequently take twice as long as other leadership roles.

This scarcity makes early engagement with an external SaMD regulatory consultant a pragmatic bridge. A consultant helps define regulatory strategy early (classification, submission type, QMS setup), prevents costly rework, and ensures documentation meets FDA standards before submission.

5.3 Key Roles & Hire Sequencing (12–18 Month Plan)

Wave 1 — Months 1–6: Foundation (4 Hires + 1 Advisor)

Wave 2 — Months 6–12: Scale (3 Hires)

Wave 3 — Months 12–18: Growth Infrastructure (2–3 Hires)

5.4 Advisor & Board Recruitment

Tempo needs advisors who open doors, not just lend names. Investors are demanding clinical traction, capital efficiency, demonstrable buyer urgency, and FDA-pathway readiness — advisors who accelerate all four signals in parallel are high-leverage assets.

5.5 Equity & Compensation Considerations

Key Compensation Principles

• Use a standard 4-year vest with 1-year cliff across all equity grants to align long-term incentives.
• Set a realistic option pool of 15–20% pre-Series A to accommodate Wave 1–2 hires without over-diluting founders ahead of institutional financing.
• Benchmark cash conservatively — health-system sales cycles for ACO/hospital contracts typically run 6–18 months, meaning Tempo will likely be pre-revenue during Wave 1; preserving runway means leaning on equity compensation for senior hires.
• Regulatory and clinical roles command a non-negotiable premium. Director-level regulatory positions often remain open for months. Budget accordingly or plan for a longer search.

5.6 Clinical Evidence as a Hiring Multiplier

The team plan must be evaluated not just for operational coverage, but for its capacity to generate the clinical proof that unlocks enterprise contracts.

5.7 Hiring Roadmap — Wave Summary

Risk 1 — Regulatory: FDA SaMD Clearance Delays the AI Core

Severity: High | Likelihood: Medium

Tempo's early-warning deterioration model is the product's central differentiator and the component most likely to require regulatory clearance before commercial deployment.

Key regulatory facts:

• As of August 2024, the FDA cleared 97% of AI-enabled devices via the 510(k) pathway.
• 510(k) requires proof of substantial similarity to a predicate device (low-to-moderate risk).
• If Tempo's algorithm makes autonomous deterioration predictions rather than displaying trends, the path could shift to De Novo or, in the worst case, PMA.
• If the tool is considered high-risk (life-sustaining or high-impact), De Novo is not available and the device goes via PMA.
• FDA draft guidance from January 2025 proposes lifecycle management considerations for AI-enabled medical devices — adding compliance overhead that did not exist for earlier-generation RPM competitors.

Mitigations:

1. Engage FDA early via the Pre-Submission (Q-Sub) program to confirm device classification and identify viable predicates before significant R&D investment.
2. Architect the AI layer as a clinical decision support (CDS) tool that surfaces risk scores to clinicians rather than issuing autonomous alerts — a design approach that may keep the product in a lower-risk classification.
3. Prepare a Predetermined Change Control Plan (PCCP) from day one so future model improvements do not require fresh clearances.
4. If clearance timelines stretch, launch using the connected scale and blood-pressure cuff (already-cleared hardware) with a rules-based alert layer, generating real-world data to support the SaMD submission.

Risk 2 — Reimbursement: CPT Code Rate Compression or Rule Changes Erode ARPU

Severity: High | Likelihood: Medium

Key reimbursement facts:

• Tempo's revenue model rests on CMS reimbursement through CPT codes 99453, 99454, and 99457.
• CMS proposed several payment policy changes for remote monitoring services in the CY 2026 Physician Fee Schedule, with new payment rates proposed effective January 1, 2026.
• All remote monitoring codes are expected to be reviewed again at the CPT Editorial Panel's January 2028 meeting — a full repricing event that sits squarely within Tempo's three-year ramp window.
• On the positive side, the 2026 PFS Proposed Rule suggests updates that reduce operational hurdles and increase flexibility for providers, demonstrating CMS support for remote monitoring.

Mitigations:

1. Model a downside ARPU scenario of $110–$130/month (reflecting a 25–30% rate cut) in all financial planning and ensure unit economics remain viable at that floor.
2. Pursue value-based contract structures with hospital buyers (e.g., per-avoided-readmission fee or shared-savings model) to partially decouple revenue from fee-for-service CPT rates.
3. Bundle Tempo with Chronic Care Management (CCM) billing — CCM codes can be billed concurrently with RPM when at least 20 minutes are spent with the patient performing appropriate tasks, supporting dual reimbursements.

Risk 3 — Policy: HRRP Penalty Reform Removes the Primary Buyer Pain Point

Severity: High | Likelihood: Low–Medium

Key policy facts:

• Tempo's B2B value proposition is built on hospital urgency created by HRRP financial penalties.
• Research shows that after adjusting for unobserved selection, hospitals in the highest Medicare Advantage penetration quintile would be penalized $26,915 less, with penalty redistributions amounting to $284–$297 million annually — a distortion argument advocacy groups have used to lobby for HRRP reform or elimination.
• A future Congress or CMS administration could restructure or repeal the program, vaporizing the compliance-driven urgency that makes hospital procurement conversations short.

Mitigations:

1. Diversify the commercial narrative beyond HRRP — position around ACO shared-savings, CMS Star Ratings improvement, and payer-driven readmission penalty clauses in commercial contracts.
2. Target ACOs and integrated delivery networks (IDNs) alongside HRRP-penalized hospitals — these buyers face readmission cost pressure regardless of HRRP because readmissions consume their own capitated budgets.
3. Build ROI calculators anchored to cost-per-readmission avoided ($15,000–$25,000 per event) rather than penalty-specific language, so the value case is self-standing.

Risk 4 — Competition: Established RPM Platforms Entrench Before Tempo Reaches Scale

Severity: Medium–High | Likelihood: High

Key competitive facts:

• Larger RPM vendors can replicate Tempo's core features (connected scale + BP cuff + care-team alerting) within existing contracts, potentially at zero marginal cost to the hospital.
• Health systems have already signed multi-year contracts with entrenched platforms.

Mitigations:

1. Lead with the AI model as the defensible moat — invest early in clinical validation studies (ideally a prospective trial) demonstrating that Tempo's fluid-retention alert algorithm outperforms generic RPM threshold-alerting. Published outcomes data is the hardest thing for generalist RPM vendors to replicate quickly.
2. Pursue a narrow beachhead strategy — focus initial sales exclusively on hospitals that received HRRP penalties *specifically for heart failure* rather than attempting to sell broadly across all 2,500+ penalized accounts.
3. Explore FDA Breakthrough Device Designation for Tempo's AI algorithm — if granted, it confers a commercial credibility signal that broad-platform competitors cannot easily claim.

Risk 5 — Clinical & Liability: Alert Fatigue and False Positives Erode Care-Team Adoption

Severity: Medium–High | Likelihood: Medium

Even a clinically sound algorithm can fail commercially if it generates alert volumes that overwhelm already-stretched cardiac care nurses and physicians. False positives drive clinicians to ignore alerts — creating both a patient safety liability and a churn risk at renewal. A missed true-positive preceding a patient death creates severe legal and reputational exposure.

Mitigations:

1. Tune the alert model to a clinically meaningful PPV threshold agreed upon with clinical advisors before launch; be transparent with health system buyers about sensitivity vs. specificity tradeoffs.
2. Design a tiered alert system (e.g., "monitor closely" → "call patient" → "escalate to physician") that routes low-acuity signals to care coordinators rather than attending cardiologists, reducing cognitive load on the highest-cost staff.
3. Include contractual liability carve-outs in health system agreements that clearly define Tempo's role as a clinical decision support tool and place final clinical judgment responsibility with the licensed provider.
4. Build alert volume and PPV metrics into the customer success dashboard so care teams can see model performance over time — making accuracy a retention feature rather than a hidden variable.

Risk 6 — Patient Adoption: Elderly CHF Patients Disengage from Daily Monitoring

Severity: Medium | Likelihood: Medium–High

Key patient adoption facts:

• Tempo's clinical model requires CHF patients — predominantly Medicare-enrolled seniors — to weigh themselves, take blood pressure readings, and complete daily symptom checks consistently.
• CMS requires the device to be reliable, valid, and capable of automatically collecting and transmitting physiologic data; self-reported data alone is not sufficient for RPM billing.
• A patient who stops using the scale for two weeks triggers a billing gap and a clinical blind spot during a period when deterioration could be accelerating.

Mitigations:

1. Choose hardware with passive data capture (e.g., a connected scale that transmits automatically when stepped on, requiring no buttons or app interaction) to minimise the behavioural compliance burden.
2. Design the patient engagement program with a 20-day compliance target to build in a buffer above the 16-day CMS billing threshold.
3. Invest in live patient onboarding by a care coordinator (billable under CCM codes) and automated nudges (SMS/voice) when daily readings are missed; assign non-compliance alerts to a patient success team, not the clinical care team.
4. Track patient engagement rates as a primary KPI in pilot programs and use the data to stress-test ARPU and SOM assumptions before committing to scale.

Section 5: Roadmap & Milestones

Phase 1 — Foundation

*"Build what the FDA and CMS will accept, not just what works."*

Timeline: Months 1–12

This phase is entirely pre-commercial. The central deliverable is a defensible regulatory and reimbursement foundation — without it, neither hospitals nor ACOs will sign contracts.

Phase 1 Milestones

M1 — Regulatory Pathway Determination (Month 2)

Engage FDA via a Pre-Submission meeting (Q-Sub) to confirm whether Tempo's AI deterioration-prediction algorithm requires 510(k) clearance as a Software as a Medical Device (SaMD), or whether it qualifies for enforcement discretion as a lower-risk decision-support tool. FDA approval costs for SaMD typically range from $50,000 to over $5 million, depending on whether the product follows the 510(k), De Novo, or PMA pathway and whether clinical trials are required. Choosing the wrong pathway at Month 2 can cost a year. The FDA granted clearance to 295 AI/ML-enabled medical devices in 2025; the 510(k) route for a cardiac SaMD with existing predicates is the most likely path, but must be confirmed with counsel.

M2 — Predicate Search & 510(k) Pre-Submission Package (Month 4)

Identify cleared cardiac monitoring SaMD predicates; commission regulatory consultants to draft the pre-submission package. 510(k) clearance for Class II devices with substantial equivalence to existing products carries estimated total costs of $500K–$2M if no clinical data is required. Budget conservatively toward the higher bound, since a fluid-retention prediction model will need clinical validation data. 510(k) preparation runs 60–90 days; a pre-submission review takes approximately 90 days; the expected timeline for completing FDA multiple reviews and clearance is 140–180 working days.

M3 — HIPAA/QMSR Compliance Architecture (Month 5)

Stand up data infrastructure to ISO 13485:2016 standards. On February 2, 2024, the FDA rolled out the QMSR rule aligning Quality System Regulation with ISO 13485:2016, with manufacturers required to meet these requirements by February 2, 2026. Any device-software pairing shipped after that date must comply.

M4 — CMS Billing Architecture Confirmed (Month 6)

Lock in the RPM CPT billing stack that Tempo's hospital partners will use to recoup program costs. Six key CPT codes cover remote patient monitoring: 99453, 99454, 99457, 99458, 99445, and 99470. RPM devices must automatically collect and transmit physiologic data; manually recorded data does not qualify. The patient must use the RPM device for at least 16 days a month to bill for CPT codes 99453 and 99454. Tempo's device onboarding and engagement model must be designed around this threshold from day one.

M5 — Clinical Validation Cohort Enrolled (Month 9)

Partner with 1–2 academic medical centers or large cardiology practices to run a prospective observational cohort of 200–400 CHF patients. This produces the clinical evidence package needed for the 510(k) submission and the outcomes data that health system procurement teams will demand. The 22.3% 30-day readmission rate in the target population gives a high baseline to beat — and a concrete ROI story to sell against.

M6 — Seed / Series A Financing Closed (Month 10)

Close initial institutional capital sufficient to fund Phase 1 and Phase 2 through first commercial contract. Pre-revenue medical device / digital health companies at the 510(k) stage typically raise $5M–$20M at seed/Series A. Clinical validation data and a regulatory filing in process are the expected proof points.

Phase 2 — Launch

*"Sign the first three contracts. Prove the model works in a real health system."*

Timeline: Months 13–24

The objective is commercial proof-of-concept: 3–5 signed hospital or ACO contracts, 500–2,000 patients enrolled, and early readmission-reduction data in hand.

Phase 2 Milestones

M7 — FDA 510(k) Clearance Received (Month 14–16)

The anchor milestone for commercial launch. Without it, the product cannot be marketed as a medical device, and hospital procurement will stall. Under MDUFA V, the FY2026 standard 510(k) fee is $26,067 ($6,517 for CDRH-certified small businesses). Clearance also triggers the ability to formalize the reimbursement story with hospital CFOs.

M8 — First Three Health System / ACO Contracts Signed (Month 16–20)

Target hospitals already penalized under HRRP — the 2,583 hospitals that received FY2024 penalties are the most motivated buyers. Lead with the financial argument: the HRRP max penalty is 3% of all Medicare DRG payments, and each avoided CHF readmission saves $15,000–$25,000. The average healthcare IT procurement process runs approximately 125 days. Pilot programs typically precede full enterprise rollout, so Month 16–20 targets represent signed pilots, not full-fleet deployments.

M9 — 500 Patients Enrolled and Transmitting Data (Month 20)

The operational proof point. 85% of large hospitals are now using some form of RPM, which means health systems have RPM workflows — but CHF-specific, AI-alert-driven programs are still differentiated. The enrollment rate across pilot sites validates device onboarding, patient adherence, and the 16-day-per-month transmission threshold required for CMS billing.

M10 — First Readmission Outcome Data Published / Available (Month 22–24)

Generate a preliminary outcomes report from pilot cohorts. Even a 3–5 percentage-point reduction in the 22.3% 30-day readmission rate translates to a compelling ROI case for the next 50 prospects. This data becomes the centerpiece of all subsequent sales conversations.

M11 — Revenue Trickle Begins (Month 18–24)

With CMS billing validated and patients enrolled ≥16 days/month, pilot-site hospitals begin billing RPM CPT codes. At 500 enrolled patients and ~$150–$200/month ARPU, monthly revenue is approximately $75K–$100K — meaningful as a run-rate proof, not yet at scale.

Phase 3 — Traction

*"Scale what works. Move from pilot-site novelty to repeatable enterprise motion."*

Timeline: Months 25–42

The objective is to exit Year 3 with 100,000–150,000 active patients enrolled across 50+ hospital and ACO accounts — the lower bound of the SOM estimate — and a replicable sales playbook.

Phase 3 Milestones

M12 — 50+ Health System / ACO Accounts Signed (Month 30)

Expand from pilot-site beachheads to multi-site rollouts and new-logo acquisition. ACOs are responsible for the total cost of care through Medicare Shared Savings Program; RPM allows them to mitigate avoidable ER visits, readmissions, and high-cost hospitalizations, enhancing their shared savings. CMS continues to push toward its goal that all Medicare beneficiaries be under a value-based contract by 2030 — every year that passes, the ACO sales motion becomes easier.

M13 — 50,000 Active CHF Patients Enrolled (Month 32)

The halfway marker toward the 100,000–150,000 SOM patient assumption. At 50,000 patients and $150–$200 ARPU, Tempo generates approximately $7.5M–$10M monthly recurring revenue (~$90M–$120M annualized). This milestone also triggers the clinical data flywheel: a 50,000-patient cohort produces publishable outcomes evidence that accelerates the remaining sales pipeline.

M14 — Series B Financing Closed (Month 28–32)

Outcomes data from Phase 2 and a growing revenue run-rate support a Series B raise to fund national sales expansion, device supply chain at scale, and a clinical operations center. The financing round also provides runway to absorb any reimbursement headwinds from the 2027 CMS final rule.

M15 — 100,000–150,000 Active Patients Enrolled (Month 38–42)

SOM target achieved. At this scale, Tempo's annual revenue reaches $180M–$360M — the 4–9% capture of the ~$4.1–4.7B cardiac RPM SAM defined in the brief. This milestone also validates the hypothesis that a focused B2B2C CHF program can carve a defensible niche within the broader U.S. RPM market, which is projected to reach $29.13B by 2030 at a 12.6% CAGR.

M16 — Peer-Reviewed Clinical Outcomes Published (Month 36)

A 2-year retrospective study on Phase 2 and early Phase 3 cohorts, targeting JACC or a comparable cardiology journal. This de-risks the product for hospital procurement committees that require clinical evidence, and positions Tempo as the evidence-based standard in CHF RPM — a durable competitive moat.

Full Roadmap Summary

Overview

Tempo is positioned at the intersection of three structural forces: a growing CHF epidemic, Medicare's financial penalties for readmissions (HRRP), and a rapidly expanding RPM market. The primary exit path is a strategic acquisition by a large MedTech, health-system technology, or managed-care acquirer seeking a clinically validated, reimbursement-native CHF workflow. A secondary path — independent IPO or SPAC listing — becomes viable only at significant revenue scale with demonstrated clinical outcome data. A third path, PE recapitalization, is a viable bridge if growth stalls before a strategic buyer emerges.

Likely Acquirer Archetypes

Comparable M&A Transactions & Market Signals

Valuation Multiples Reference

The Strategic vs. Financial Narrative

For a strategic acquirer (MedTech OEM): Tempo is not primarily a revenue asset — it is a customer relationship and penalty-mitigation asset. A cardiac device company already selling to the same health systems can use Tempo to: (1) deepen hospital stickiness through a recurring software contract, (2) capture the RPM CPT billing stream as a managed service, and (3) own the pre-hospitalization data layer that complements in-hospital device data. Notably, the cardiology segment accounts for the largest share — 29% — of the U.S. RPM market. Any large cardiac OEM lacking a remote monitoring software platform is structurally exposed to competitors who have one.

For a managed-care acquirer: The logic is actuarial. Tempo's model directly reduces inpatient claims spend that payers absorb under value-based contracts. A payer that internalizes Tempo can deploy it across its Medicare Advantage CHF enrollees without paying a health-system intermediary.

For a financial acquirer (PE): Tempo's recurring ARPU model — anchored in CMS reimbursement codes — provides durable, government-backed revenue. Well-documented RPM programs can add 10–15% to valuations due to their recurring revenue nature. A PE sponsor would target margin expansion through operational leverage before re-running a strategic sale process at a higher multiple.

Milestones That Make Tempo Acquirable

*Sequenced in order of acquirability readiness. No timeline is implied — these are preconditions, not a calendar.*

Exit Path Summary

1. The Strategic Case for Raising Now

Tempo checks all three macro tailwinds: it is AI-native, has a clear CMS reimbursement path via existing RPM CPT codes, and sells into an institutional B2B market (hospitals and ACOs). The CMMI ACCESS Model — launching July 2026 — offers a 10-year Medicare value-based payment pathway for digital health interventions targeting chronic conditions, a program Tempo is purpose-built to enter.

2. The Revenue Engine: CMS Reimbursement Rates

3. Fundraising Strategy: Two-Phase Approach

4. Seed Round — Work Streams

5. Seed Round — Use of Proceeds

6. Series A — Work Streams

7. Series A Unlock Milestones — What the Seed Must Achieve

8. Investor Profile & Strategic Fit

9. Risks of Delaying the Raise

10. Summary: The Ask